TWiV explains what is known about cases of acute, severe hepatitis of unknown origin in children, and discovery of an inhibitor of TMPRSS2 protease that blocks SARS-CoV-2 infection.
Hosts: Vincent Racaniello, Alan Dove, Kathy Spindler, and Brianne Barker
Click arrow to play
Download TWiV 894 (60 MB .mp3, 100 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Severe hepatitis in children (WHO) 2:48
- TMPRSS2 inhibitor (Nature) 18:45
- Omicron less dependent on TMPRSS2 (TWiV 879) 20:46
- Letters read on TWiV 894 54:37
- Timestamps by Jolene. Thanks!
Weekly Picks 1:25:29
Brianne – Apple AirTag
Kathy – Dental art/sculpture/mobile/chandelier
Alan – Vintage Radio and Communications Museum of Connecticut
Vincent – For the Love of Enzymes by Arthur Kornberg
Intro music is by Ronald Jenkees
Send your virology questions and comments to twiv@microbe.tv
I was interested in your discussion of a new TMPRSS2 inhibitor candidate for coronavirus therapy. I recently reviewed some of the agents that have been considered as possible coronavirus therapeutics targeting fusion and entry. My review preceded publication of the article you discussed. My review reference is as follows:
Hawley HB. Coronavirus fusion and entry are targets for new therapies. Ann Public Health Reports 2022;6(1):249-253.